Novel therapies which target B-cell receptor (BCR) signaling, such as an oral Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, demonstrate impressive activity in treatment of CLL [2]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.